Result reactions - booking profits on good results + good outlook is classic short-term retail thinking. Use results to weed out losers, but hold onto your winners for god’s sakes!
77
Correspondens retweeted
never could have thought that the real estate balance sheets in India will be almost debt-free. basically India inc balance sheet is cleanest as ever with system credit growth above 20% - what a deadly combination.
Great results season overall! Don’t let a few rotten apples at the end cloud your perception. Earnings were strong in a very tough environment. Market is taking double and triple digit growth for granted, plenty of opportunities with full clarity now 🧿
187
This is mostly accurate. Came to the same conclusion reading past filings. The Quick Pay order is fake and was used to dress the books for IPO. SEBI must investigate
🚨 MILLWORK TECHNOLOGIES – CONSPIRACY THEORY. 👁️Staring at Rs.100Cr Hole in the Wall
First the background, which everybody chose to ignore because there was a lot of hype driven by massive Rs.160Cr issue
Originally, the promoters founded V3 Technologies in 2015. The business was pretty bad and grew VERY SLOWLY to Rs.9.6Cr in Fy24 and 22Cr in Fy 25. YES Rs.22Crore ONLY in FY25.
In between, in FY 22, Promoters founded MILLWORKS TECHNOLOGIES but continued to carry out the works under V3 Technologies only, “grinding” their way to Rs.22Cr.
V3 Technology’s manufacturing Unit was taken on Lease in Millworks Name, in January 2024 only.
2 More small sheds (Unit 2 & Unit3) with machining equipments in Peenya were taken on lease in March and Nov 2024 .
Then in Jan 2025 it took on lease Unit 4 shed which is somewhat large with aim to expand business using proposed IPO funds. Since there was not much business operation, part of this UNIT 4 has been leased out (even now to a third party) for Rs.65,000 per month. PLEASE NOTE THIS!! 😆
So we can see, the company has small workshops only which generated Rs.22Cr max in Fy25. (The large Unit was not operational because machines are not there and needed funds to buy)
To buy large number of CNC Machines huge funds are needed (IPO was estimated for Rs.160Cr).
With measly Rs.22Cr turnover, it is impossible to raise Rs.160Cr from market
That is the background which all of us IGNORED due to the hype.
Now the CONSPIRACY THEORY! 🚨
With insignificant machining business in old run-down sheds, the people behind, must have come up with idea to cook the books and show HUGE turnover in FY26 with fake orders.
A company with pitiable machining capacity and 22Cr turnover in FY25, SUDDENLY BALLOONED to Rs.148Cr in Fy26. WOW! 😜
Considering the lame duck business growth history of V3 Technologies as well as the promoters, we can assume company, at best, would have got around 40 to 45Cr orders in FY26, with addition of sheds (Unit 2 &3) (ie Against Rs.22Cr reported in Fy25)
Even with Rs.45Cr, it will not be enough to raise 160Cr in IPO. No one will accept that. So another 100Cr must have been COOKED UP. Out of this 100Cr around Rs.70Cr is mentioned as work order from QUICKPAY SERVICES for Drone Parts in the RHP. Rest is not specifically stated. But from Auditor comments around Rs.97.5Cr is fake.
Since MILLWORKS has NO machining capability to make drone parts, it is stated in RHP, that this work is being done by Chennai based BIG BANG BOOM TECHNOLOGIES. (this should have been a RED Flag for Investors. Such a BIG Over HYPED company has no capability??) 🚨
Now, it can be safely presumed, there is absolutely NO NEED for QUICKPAY which has to supply high security, high performance drones to the Defense Forces, to place order on a incapable company like MILLWORKS, only to get it made by BIG BANG! 😜
From the AUDITOR QUALIFICATION it is obvious that there is no substance or back up for this order. 🚨
“We could not obtain sufficient and appropriate evidence about whether the trade receivables and the advances due from this party are recoverable” - Auditor🚨
In simple terms, these are fraud entries. (This is Conspiracy Theory) That is about Rs.97.5Crore.
This means, QUICKPAY went ahead and got works done by BIG BANG BOOM and MILLWORKS is NOWHERE in the picture. 🚨
Whatever money is collectable as per books, is NOT COLLECTABLE at all, since QUICKPAY must have already paid money for the works to BIG BANG and it got the stuff made by them. (this is CONSPIRACY THEORY) 😆
Since Millworks does not have precision machining capability to do such works, anyway it could not have done the job. (If it had capability, it would have done the job by itself)
So, we have an IPO, claiming company has Rs.148Cr turnover in Fy26 but with an almost Rs.100Cr HOLE in that.
May be, like in the case of C2C, @sebi_updates need to have a serious look at this fiasco, to check whether there is any substance in the conspiracy theory, especially since Auditor has raised RED FLAG.
REMEMBER, THIS IS CONSPIRACY THEORY!! DON’T BELIEVE THIS. 👍
3
317
Q-Line is buying 70% of promoter group company "Heidelco Medicore" for 26 cr. According to the press release, Heidelco did 108 cr revenue and 7.9 cr PAT in FY26, so they are selling it to listed entity at p/e of 5x. How generous 😇
6
726
Correspondens retweeted
Replying to @Priyansh_Miri
For me it’s simple, even if you sniff a small discrepancy or doubt, skip. There were some noise during ipo, I skipped it not because I doubt or something, but because there is no dearth of opportunities
Very good Q2 from KDDL. Another company that can become very large. Tweet below covers what they do well -
KDDL: A play on precision engineering
and Premium Watches
As many of you are aware, KDDL is the holding company of Ethos, India's leading premium watch retailer.
However, KDDL on a standalone basis is a very interesting company by itself.
The 2 key main divisions are:
Taratec division: watch components
Core division for watch components like dials, hands. They have recently forayed into bracelets which is growing fast.
The premium watch market has been facing some headwinds, but is expected to recover from FY27 onwards. Overall, this division is supposed to have a steady 10-12% growth. If the premium watch market recovers faster, then growth can be higher
Eigen: Precision engineering division
This division is what I am most excited about. FY26 revenues was 200 cr, a growth of 35%. Going forward also, this division is expected to grow at 25% CAGR.
This division caters to - EV, Energy storage, Electronics, Aerospace etc.
High entry barrier, niche precision stamping and tooling with a huge TAM.
Ornapack: This is a new division for luxury packaging with only 23 Cr revenue in FY26 but growing fast at 35%+. Growth is expected to be robust with opportunity size of 80-100 Cr.
Favre-Leuba: This is a Swiss luxury watch brand, which KDDL has acquired. Current revenue is negligible but can be a significant optionality based on how well they can revive this.
Valuations and opportunity
This is where it gets interesting..
Current Market Cap of Ethos is 7100 Cr.
KDDL's share is 50% = 3550 Cr.
KDDL's marketcap is only 4000 Cr.
Lets apply a holding company discount of 50%
Then KDDL's share in Ethos is 1800 Cr.
So, KDDL's own market cap is 2200 Cr which means
the standalone company is available at PE of 27-28.
For a high entry barrier precision manufacturing company growing at 20%+, this is very reasonable considering how overvalued some of the precision manufacturing companies are...
Also, if the luxury watch market recovers, then KDDL also benefits as Ethos stock price moves up
Technically, the stock is on a strong stage 2 uptrend since Q4FY26 results but still trading below ATH levels of 2024.
Disc: Not invested. Do your own research, this is not a recommendation.
4
330
Correspondens retweeted
Q-Line Biotech ⛳️
There is a reason they listed on SME and not main board
1) Promoter group has a very shady history
2) Auditor flagged 15cr guarantee as prejudicial
3) 66% sales are to related fraud party
4) Bank filings differ from books
5) CFO 29% of PAT
🧵 India's biggest-ever SME IPO opens this week.
Q-Line Biotech (#QLine): set to raise ₹214 Cr. of fresh issue with marquee anchor investors (#abakkus #carnelian #HDFC #360One) & many more.
Skip the hype and a deep dive into RHP raises serious concerns investors need to consider while evaluating the IPO for investment
🚩A company that sells 65% to its own group → guarantees ₹46 Cr of that group's debt → can't convert profit to cash → sits on 10 months of inventory → gets downgraded 4 notches by CRISIL → shares an office with an IT-raided entity it claims to have exited → belongs to a group named in a ₹500–700 Cr pathology scam → and books a ₹17 Cr loss it won't explain.
🚩 #1 — It sells 65% to its own group: POCT Services
283 distributors on paper. In reality, one group entity — POCT Services — absorbs more than 60%+ of all sales.
% revenue share, year by year:
▪ FY23: 37.9%
▪ FY24: 51.7%
▪ FY25: 62.9%
▪ 9M FY26: 65.4%
This isn't a distribution network. It's a related party. And the dependence deepens every single year — the opposite of what you want to see before an IPO.
🚩 #2 — It also backstops that group's debt
It sells to the group. Does it also stand behind the group financially? Yes.
Corporate guarantees in the contingent-liability note:
▪ POCT Science House: ₹10.6 Cr (Mar'25) → ₹15 Cr (Dec-25)
▪ POCT Services: ₹31.05 Cr (brand new in Dec-25)
▪ Total: ₹46 Cr — up from ZERO in FY23 & FY24
See the loop: Q-Line books revenue selling to POCT, and simultaneously guarantees POCT's borrowings. Revenue and risk circulate inside the same family. If POCT stumbles, Q-Line — and now its public shareholders — are on the hook
🚩 #3 — The profits don't become cash
A healthy business converts profit into cash. This one doesn't.
Net cash from operations:
▪ FY23: +₹25 Cr
▪ FY24: −₹24 Cr ❌
▪ FY25: −₹1.3 Cr ❌
▪ 9M FY26: −₹33 Cr ❌
Three straight years of negative operating cash flow — Reported profit on the P&L, real cash walking out the door.
🚩 #4 — Where the cash is trapped
It's stuck in receivables and inventory that keep swelling.
Debtor days: 66 (FY23) → 96 (FY25) → 160 (Dec-25)
Inventory days: 180 (FY23) → 226 (FY25) → 305 (Dec-25)
That's ~10 months of inventory sitting idle, and customers taking 5+ months to pay.
Recall who the biggest customer is.
And the company's own projections keep debtor days at 115 through FY28. They aren't promising a fix — they're normalising the bloat.
🚩 #5 — CRISIL has already downgraded the credit rating
On April 9, 2026, CRISIL:
▪ Cut long-term: BBB+/Stable → B/Stable (four notches)
▪ Cut short-term: A2 → A4
▪ Tagged it "Issuer Not Cooperating" — the company stopped sharing information.
A four-notch downgrade, weeks before the IPO, and the firm went dark on its own rating agency. Yet it's comfortable asking the public for ₹214 Cr.
🚩 #6 — The "clean exit" that wasn't
Now the governance gets uncomfortable.
The Income Tax Dept ran search & seizure operations on POCT Science House Pvt Ltd (Sep 2–5, 2025); books and records were impounded.
Q-Line says it divested its 49% stake on Mar 20, 2025 — a clean break.
Except:
▪ POCT Science House still operated from the SAME office as Q-Line
▪ Its guarantee from Q-Line ROSE from ₹10.6 Cr (Mar'25) to ₹15 Cr (Dec'25) — AFTER the supposed exit
If you've genuinely walked away, why the shared address — and why put MORE money on the line for them?
🚩 #7 — And the group has a documented history
This is where it stops being about accounting. An NDTV investigation (Sep 6, 2025) into Madhya Pradesh's govt pathology-lab scandal names the winning consortium as "Science House Medicos and POCT Services." NDTV reported:
▪ 85 govt labs billed at premium NABL rates — NONE were NABL-accredited at contract start
▪ Scam estimated at ₹500–700 Cr, with ≥₹300 Cr in overbilling
▪ FDA-approved machines required, never used; single-bidder re-tender rule ignored
▪ Science House's promoter had served jail time for corruption; POCT blacklisted in multiple states
▪ The Economic Offences Wing had already filed a case
"Science House" is a JV of Q-Line with its erstwhile associate POCT Science House.
ndtv.com/india-news/ndtv-exc…
⚠️ #8 — The ₹17 Cr that simply vanished
One number we could not reconcile.
The restated P&L books an Extra-Ordinary Item of ₹16.97 Cr (~₹17 Cr) in FY25 — large enough to drag PAT down from ~₹34 Cr (FY24) to ~₹28 Cr (FY25). We searched the RHP for what this loss actually was but couldn't find the answer.
🔍 #9 — And note where it chose to list : SME and not Mainboard!
A ₹214 Cr raise is the largest SME IPO in history.
The minimum lot here is ~₹2.74 lakh — which prices out small retail and the questions they'd bring.
A record-sized raise, riding the lighter-scrutiny lane, with a ticket size that keeps the smallest investors out. Not illegal.
Summary : Are we reading too much or lining all the flags are telling one coherent story, not eight random ones!
Do your own work. This is educational analysis, not investment advice. 🙏 #QLineBiotech #SMEIPO #IPO #IndianEquities #NSESME #StockAlertsIndia #stockmarkettrading
Update on automated extraction and sample to answer systems by 3B BlackBio. With this, they are evolving from a molecular product supplier to a proprietary diagnostic automation platform. These machines are placed at large labs like AIIMS and ensure steady repeat business.
3B BlackBio Dx 🧬
I have been studying the Sample to Answer technology they are developing.
This automates the lab process from a patient sample to a molecular test result. Top players are MNCs - Roche, Grifols.
This is a long term bet. Put together a infographic to explain 👇
6
540
Correspondens retweeted
3B BlackBio delivers strong Q2 results 🚀
Revenue grows 42%, EBITDA jumps 43% and PAT rises 21%
EBITDA margin sustains above 43%, while sequential performance shows sharp recovery
3B BlackBio DX Q2FY27
Revenue ₹48 Cr
+42% YoY
EBITDA ₹21.06 Cr
+43% YoY
EBITDA Margin 43.61%
vs 43.45% YoY
PBT ₹24.30 Cr
+24% YoY
PAT ₹18 Cr
+20% YoY
Strong revenue growth with EBITDA margins holding above 43%.
Sequentially, revenue grew 44%, EBITDA jumped 147% and PAT doubled.
Verdict: STRONG RESULTS, EXCELLENT SEQUENTIAL MOMENTUM 🚀
18 cr PAT for 3B Blackbio vs 8 cr for Molbio in Q2
900 cr enterprise value vs 17,000 cr
Replying to @correspondens
The best listed co in diagnostics manufacturing remains 3B BlackBio because of their honest management. Never misguided.
They should deliver more profit this quarter than Molbio. 1,000 cr market cap vs 16,000 cr.
2
741
Blockbuster quarter from 3B Blackbio
- 53 cr rev, 18 cr PAT in Q2 vs 39 cr revenue, 9 cr PAT in Q1
- Coris turned around, losses down 45%
- 270 cr cash on bs, market cap only 1100 cr
- Strong cash flows from ops
Very undervalued and US FDA + M&A triggers havent even started yet
3B BlackBio
Expecting Q2 revenue of ~40 cr (vs 33 cr in Q1). EBITDA margins should improve as well QoQ. YoY is not comparable on margin & profitability due to Coris acquisition last yr. Q3 and Q4 will be comparable and they should show PAT growth.
6
571
Can be Adani’s greatest legacy
🚨 BIG: 🇮🇳 Adani Group will invest $4-5 billion in the first phase of Dharavi's redevelopment, Pranav Adani told Fortune India.
The project involves building over 1.5 lakh residential and commercial units, covering more than 200 million sq. ft.
The redevelopment aims to rehabilitate residents over approximately 7 years, alongside developing schools, hospitals, parks and modern urban infrastructure.
2
391
Today is a good day to remind everyone how Millworks PR team got negative tweets deleted post IPO.
6
1,137
3B BlackBio
Expecting Q2 revenue of ~40 cr (vs 33 cr in Q1). EBITDA margins should improve as well QoQ. YoY is not comparable on margin & profitability due to Coris acquisition last yr. Q3 and Q4 will be comparable and they should show PAT growth.
Correspondens retweeted
Appreciating Rupee
End of War
Crude Crashing
Tax cut Rumours
Good Results
Trump's Loss
For the last 10-15 days market has digested a barrage of positive news.
Correspondens retweeted
🚨 62 BSE SME COMPANIES – MARKET LOT SIZE REDUCTION EFFECTIVE NOVEMBER 16, 2026 📢
The exchange has revised the lot sizes for standardisation of lot sizes in SME stocks.
🔹 The revised market lots will allow trading members and investors to trade in smaller quantities compared to the existing lot sizes.
📊 The attached notification contains the complete list of 62 companies, along with their existing and revised market lot sizes.
Important: Investors and traders dealing in BSE SME stocks should take note of these changes before the effective date.
Disclaimer: This is shared for educational and informational purposes only.

































